United Bank (Virginia)’s Seelos Therapeutics, Inc. Common Stock SEEL Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2023
Q3
Sell
-7
Closed -$31.3K 156
2023
Q2
$31.3K Hold
7
﹤0.01% 151
2023
Q1
$18.1K Hold
7
﹤0.01% 157
2022
Q4
$17.8K Hold
7
﹤0.01% 155
2022
Q3
$27K Buy
+7
New +$27.5K ﹤0.01% 155

Other funds holding SEEL

United Bank (Virginia)'s SEEL Position: Q3 2023 in Review

United Bank (Virginia) sold out of Seelos Therapeutics, Inc. Common Stock (SEEL) in Q3 2023, closing a stake of 7 shares — an estimated $31.3K sold.

United Bank (Virginia) first reported a position in SEEL in Q3 2022 and held it in 4 quarters. The position peaked at $31.3K in Q2 2023. 67 funds tracked by Wall St. Rank hold SEEL as of Q3 2023.

  • United Bank (Virginia) reported no remaining Seelos Therapeutics, Inc. Common Stock position as of Q3 2023 after selling out during the quarter.
  • United Bank (Virginia) sold 7 Seelos Therapeutics, Inc. Common Stock shares in Q3 2023, an estimated $31.3K.
  • United Bank (Virginia) first reported a position in Seelos Therapeutics, Inc. Common Stock in Q3 2022 and held it in 4 quarters.
  • United Bank (Virginia)'s Seelos Therapeutics, Inc. Common Stock position peaked at $31.3K in Q2 2023.
  • 67 funds tracked by Wall St. Rank held Seelos Therapeutics, Inc. Common Stock as of Q3 2023.

Based on United Bank (Virginia)'s 13F filing for Q3 2023, filed 8 Nov 2023.